Strategic Pharma Partnerships Alto's Precision Psychiatry Platform uses AI-derived brain biomarkers and multimodal data to match patients with effective treatments. This capability is highly attractive to pharma companies seeking trial enrichment, faster signal detection, and potential co-development of precision medicines for neuropsychiatric disorders. Target pharma R&D teams for collaboration or licensing to improve trial outcomes and accelerate approvals.

Biomarker Data Licensing The platform integrates EEG, wearables, behavioral patterns, and genetics. This rich biomarker dataset and analytics capability can be commercialized to CROs, academic centers, and device partners as data services or companion diagnostic development partnerships, enabling safer, more targeted studies and new revenue streams.

Trial Collaboration Opportunities With Phase 2a data for ALTO-207 in Major Depressive Disorder and active participation in industry events, Alto has a track record to pair with sponsors for phase appropriate trials, patient recruitment acceleration, and biomarker driven endpoints. Propose joint development deals or exclusive regional rights to de risk pipeline testing.

Growth Momentum Signals Strong funding momentum and strategic governance moves signal capacity to scale partnerships, invest in data infrastructure, and expand trial networks. Use this to approach growth stage investors and strategic pharma partners with a clear expansion plan.

Industry Collaboration Ecosystem Alto is positioned in precision psychiatry with growing industry recognition and conference presence. Leverage KOL relationships, award visibility, and the platform's robust data capabilities to propose integrated platform collaborations with pharma, CROs, and academic partners.